LUYE PHARMA(02186),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02186 LUYE PHARMA

Not Yet Opened 05-20 16:08:03

2.260

-0.020

-0.88%

High2.280	Low2.220	Vol10.36M
Open2.280	D1 Closing2.280	Amplitude2.63%
Mkt Cap9.03B	Tradable Cap9.03B	Total Shares4.00B
T/O23.25M	T/O Rate0.26%	Tradable Shares4.00B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02186","market":"HK","secType":"STK","nameCN":"LUYE PHARMA","latestPrice":2.26,"timestamp":1779264483003,"preClose":2.28,"halted":0,"volume":10356500,"delay":0,"changeRate":-0.008771929824561412,"floatShares":3995000000,"shares":3995000000,"eps":0.158823,"marketStatus":"Not Yet Opened","change":-0.02,"latestTime":"05-20 16:08:03","open":2.28,"high":2.28,"low":2.22,"amount":23253926,"amplitude":0.026316,"askPrice":2.27,"askSize":428000,"bidPrice":2.26,"bidSize":196500,"shortable":3,"etf":0,"ttmEps":0.17674,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1779327000000},"marketStatusCode":0,"adr":0,"listingDate":1404835200000,"exchange":"SEHK","adjPreClose":2.28,"openAndCloseTimeList":[[1779240600000,1779249600000],[1779253200000,1779264000000]],"volumeRatio":0.37694538888999773,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02186/wiki","defaultTab":"wiki","newsList":[{"id":"2635386657","title":"Shandong Boan Biotechnology launches share buyback program worth up to HK$ 200 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635386657","media":"Reuters","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635386657?lang=en_us&edition=fundamental","pubTime":"2026-05-13 21:53","pubTimestamp":1778680382,"startTime":"0","endTime":"0","summary":"Shandong Boan Biotechnology launched an open-market share buyback program of up to HKD 200 million under a repurchase mandate approved at its June 5, 2025 annual general meeting.Board cited view that current trading price undervalues intrinsic value, business prospects, or recent operating performance.Repurchased shares may be canceled, held in treasury, sold, or transferred.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on May 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL1KW16x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1606","02186","BK1191","BK1161","06955","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136842288","title":"Luye Pharma Reports Stable Share Capital and No Equity Movements in April 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1136842288","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136842288?lang=en_us&edition=fundamental","pubTime":"2026-05-07 16:45","pubTimestamp":1778143516,"startTime":"0","endTime":"0","summary":"For the month ended 30 April 2026, Luye Pharma Group Ltd. reported no changes in either its authorised or issued share capital, according to the company’s monthly return filed with Hong Kong...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124912963","title":"Luye Pharma Releases 2025 ESG Report: Governance Upgrades, Emissions Rise on Higher Steam Consumption","url":"https://stock-news.laohu8.com/highlight/detail?id=1124912963","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124912963?lang=en_us&edition=fundamental","pubTime":"2026-04-29 22:25","pubTimestamp":1777472751,"startTime":"0","endTime":"0","summary":"Luye Pharma (02186) has published its 10th Environmental, Social and Governance (ESG) Report, covering operations from 1 January – 31 December 2025. Key take-aways are as follows:  Strategic ESG...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111053161","title":"绿叶制药(02186)2025年年报：营收63.084亿元，净利同比增9.4%，深耕四大治疗领域","url":"https://stock-news.laohu8.com/highlight/detail?id=1111053161","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111053161?lang=en_us&edition=fundamental","pubTime":"2026-04-29 22:09","pubTimestamp":1777471740,"startTime":"0","endTime":"0","summary":"绿叶制药集团有限公司（LUYE...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"绿叶制药(02186)2025年年报：营收63.084亿元，净利同比增9.4%，深耕四大治疗领域","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631320548","title":"Shandong Boan Biotech publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2631320548","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631320548?lang=en_us&edition=fundamental","pubTime":"2026-04-29 22:05","pubTimestamp":1777471551,"startTime":"0","endTime":"0","summary":"Boan Biotech released annual report for year ended Dec. 31, 2025, highlighting expanded commercial footprint with five marketed biologics across oncology, metabolic disease, ophthalmology.Growth focus shifted toward new launches in second half of 2025, with dulaglutide biosimilar Boyouping cleared for China market in August 2025.Ophthalmology entry accelerated with aflibercept biosimilar Boyoujing authorized in China in November 2025 for wet AMD and diabetic macular edema.Pipeline advanced with completion of patient enrollment for China Phase 3 study of nivolumab biosimilar BA1104 in October 2025, supporting next commercialization wave.International strategy progressed with denosumab biosimilars BA6101 and BA1102 completing Phase 3 trials in US, Europe, Japan, with US BLA submissions targeted by mid-2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL29rnzs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186","BK1606","BK1191","BK1583","06955","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631326548","title":"Luye Pharma publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2631326548","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631326548?lang=en_us&edition=fundamental","pubTime":"2026-04-29 22:04","pubTimestamp":1777471487,"startTime":"0","endTime":"0","summary":"Luye Pharma annual report for year ended Dec. 31, 2025 highlighted growth driven by newer products, helped by expansion in oncology and CNS portfolios.Commercial momentum accelerated with 15 cumulative new-drug launches across multiple markets from 2021-2025, including U.S. launch of ERZOFRI in April 2025.Pipeline focus shifted toward next-generation candidates, with CNS programs LY03015 and LY03020 advancing in China studies while LY03017 secured U.S. IND clearance in November 2025.Manufacturing strategy centered on scaling global supply chain, with Germany transdermal patch site running at full capacity while “Project Miesbach 2027” added new packaging operations to double technical capacity.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal ad","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDLkj2zV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1191","BK0188","LU2148510915.USD","BK0070","002262","LU1064131003.USD","02186","BK1606","LU1064130708.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630004773","title":"Shandong Boan Bio proposes H-share restricted share unit incentive scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2630004773","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630004773?lang=en_us&edition=fundamental","pubTime":"2026-04-28 21:34","pubTimestamp":1777383250,"startTime":"0","endTime":"0","summary":"Shandong Boan Biotechnology proposed adopting a restricted share unit incentive scheme for its H shares.Board resolution dated April 28, 2026 outlined scheme funded by existing shares, not new share issuance.Plan requires shareholder approval via special resolutions at a general meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 28, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDL2NpfZW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1606","BK1583","06955","02186","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630438266","title":"Shandong Boan says China CDE accepts Phase II trial application for BA1106-BA1104 combo in NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2630438266","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630438266?lang=en_us&edition=fundamental","pubTime":"2026-04-26 18:31","pubTimestamp":1777199517,"startTime":"0","endTime":"0","summary":"Shandong Boan Biotechnology said China NMPA drug review center CDE accepted its Phase II clinical trial application for BA1106 combined with PD-1 inhibitor BA1104 in non-small cell lung cancer.Study targets driver gene-negative NSCLC as a first-line or second-line regimen.Boan plans to accelerate Phase II development following Phase I safety data showing mostly Grade 1-2 adverse events.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 26, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260426:nNDL8sTkzv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186","BK1606","BK1161","BK1583","06955","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100840496","title":"Luye Pharma launches first U.S. pharmacokinetic study for dual-acting VMAT2/Sigma-1R candidate LY03015","url":"https://stock-news.laohu8.com/highlight/detail?id=1100840496","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100840496?lang=en_us&edition=fundamental","pubTime":"2026-04-20 20:22","pubTimestamp":1776687761,"startTime":"0","endTime":"0","summary":"On 20 April 2026, Luye Pharma Group Ltd. disclosed the enrolment of the first volunteer in a U.S. pharmacokinetic (PK) bridging trial for LY03015, the company’s in-house-developed new molecular...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152735367","title":"LUYE PHARMA's Innovative Drug LY03015 Enrolls First Patient in US Pharmacokinetic Bridging Study","url":"https://stock-news.laohu8.com/highlight/detail?id=1152735367","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152735367?lang=en_us&edition=fundamental","pubTime":"2026-04-20 20:14","pubTimestamp":1776687286,"startTime":"0","endTime":"0","summary":"LUYE PHARMA (02186) announced that the first participant has been enrolled in the US pharmacokinetic (PK) bridging clinical trial for its self-developed new molecular entity, LY03015. This compound...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK4181","BK1606","BK1161","PK","06978","02186","BK1191","BK4218","BK1583","159992","03015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628228740","title":"Luye Pharma enrolls first subject in US PK bridging trial of LY03015","url":"https://stock-news.laohu8.com/highlight/detail?id=2628228740","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628228740?lang=en_us&edition=fundamental","pubTime":"2026-04-20 20:03","pubTimestamp":1776686628,"startTime":"0","endTime":"0","summary":"Luye Pharma enrolled first subject in a U.S. pharmacokinetic bridging study of LY03015, an investigational VMAT2 inhibitor and sigma-1 receptor agonist for tardive dyskinesia and Huntington’s disease.Results have not been presented; study is designed to generate safety, tolerability, and pharmacokinetic evidence to guide dose selection for planned U.S. Phase II and Phase III trials.Trial is open-label, single-dose, parallel-group in healthy Chinese and Caucasian adults, positioning LY03015 for cross-population development in U.S. regulatory pathway.Program aims to support a differentiated profile versus existing VMAT2-only therapies by combining symptom control with potential longer-lasting benefit.Luye expects to complete a Phase II trial in China soon, supporting parallel development across China and U.S. CNS pipelines.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDLbYzcr7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1191","BK1606","02186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627268263","title":"Luye Pharma Enrolls First Patient in Phase 2 China Trial of Alzheimer's Psychosis Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2627268263","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627268263?lang=en_us&edition=fundamental","pubTime":"2026-04-16 11:32","pubTimestamp":1776310364,"startTime":"0","endTime":"0","summary":"Luye Pharma  said it enrolled the first patient in a Phase 2 clinical trial in China for its investigational drug LY03017, according to a Wednesday Hong Kong bourse filing.Shares of the pharma company fell over 2% in late-morning trade Thursday.The drug is being tested for the treatment of psychosis associated with Alzheimer's disease.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02186","BK1191","BK1583","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153591250","title":"CATL Reports 48.52% Surge in Q1 Net Profit to RMB 20.74 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1153591250","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153591250?lang=en_us&edition=fundamental","pubTime":"2026-04-16 09:23","pubTimestamp":1776302616,"startTime":"0","endTime":"0","summary":"CATL (03750) plans to invest RMB 30 billion to establish a wholly-owned subsidiary for building a new energy mineral platform. Meig Smart Technology (03268) intends to invest RMB 300 million in an AI...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f2ca9b0f4a170b1d9ddb723b50e84ead","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0449515922.USD","HK0000165453.HKD","XIACY","LU0634319403.HKD","LU0143863784.USD","SG9999001903.USD","LU0244354667.USD","LU1794554557.SGD","LU2148510915.USD","LU0823040885.USD","LU1997245177.USD","LU1048588211.SGD","LU0823413660.USD","LU0828237940.HKD","BK4585","LU1961090484.USD","HK0000181138.USD","LU1769817179.HKD","LU0531970944.HKD","LU0516422366.SGD","LU1152091754.HKD","03750","LU0211977185.USD","LU1023057109.AUD","LU0049853897.USD","LU0043850808.USD","LU2580892789.USD","LU1993786604.SGD","LU2275660780.HKD","LU1102505762.USD","LU0124384867.USD","LU0052750758.USD","LU0348814723.USD","LU0326950275.SGD","CCOZY","LU2328871848.SGD","LU2257852520.SGD","BK4519","LU0672654166.SGD","LU2125910500.SGD","LU1515016050.SGD","LU0675040207.SGD","LU2238339852.HKD","SG9999001689.USD","LU0651947912.USD","LU0348816934.USD","LU0048575426.USD","LU2506952410.USD","LU0188438112.USD","LU1880383366.USD","LU0072913022.USD","IE00BPRC5H50.USD","LU0348825331.USD","LU0516423091.SGD","LU0328353924.USD","LU0307460666.USD","LU1997244956.HKD","06656","LU0302445910.USD","LU1105468828.SGD","01138","LU0572944931.SGD","01093","BK1618","LU0469268626.HKD","LU0405327148.USD","02465","LU0164872284.USD","LU0708995583.HKD","LU0106252389.USD","LU0314109678.HKD","LU1051768304.USD","LU2087589342.USD","LU0106259558.USD","LU2399975544.HKD","LU1934453819.USD","LU1255011170.USD","LU2226246903.HKD","00670","LU2506952253.HKD","LU0499858438.USD","LU0181495838.USD","LU0140636845.USD","LU0417516738.SGD","LU1813983027.USD","LU0823426480.USD","LU0405327494.USD","LU0320764599.SGD","LU1868838027.USD","LU1064131003.USD","300750","LU0823038988.USD","BK1535","LU0880133367.SGD","LU0214875030.USD","LU2298064838.USD","MIUmain","LU0370786039.SGD","LU0169518387.USD","LU0359201612.USD","LU0871576103.HKD","LU0106959298.USD","LU0823041008.USD","LU0823397103.USD","LU2495084118.USD","LU1051769294.HKD","LU0455707207.USD","LU2424517915.HKD","81810","LU0823437842.USD","LU1008478684.HKD","LU0164880469.USD","LU0348805143.USD","IE0032431581.USD","LU0823414551.USD","LU0823413587.USD","LU2097828631.EUR","LU0327786744.USD","LU2778985437.USD","IE00B8L5B284.USD","BK1589","LU2097828714.EUR","01177","LU0499858602.USD","LU0011963245.USD","LU0359201885.HKD","LU0918141705.HKD","LU0359202008.SGD","LU1770036033.HKD","LU1979443071.USD","LU0259732245.USD","LU0348827113.USD","BK1116","LU0149721374.USD","IE00B8HQ1Z84.USD","LU0593848301.USD","LU0505663152.USD","SG9999003461.SGD","LU1048596156.SGD","SG9999002463.SGD","LU0700851271.USD","LU0254981946.USD","02245","06613","002881","02298","LU0326948709.USD","BK1166","LU3063872942.SGD","LU0251143458.SGD","LU1769817096.USD","LU1880383440.USD","LU2294711713.HKD","BK1502","IE00B5MMRT66.SGD","LU2039709279.SGD","HK0000181112.HKD","IE00BZ199S13.USD","00300","LU1960683339.HKD","LU0828238088.HKD","FXCNY","LU2045819591.USD","LU0235996351.USD","IE00B29SXG58.USD","LU1978683503.SGD","LU0345775950.USD","BK4526","LU0231483743.USD","601111","BK1607","LU0543330483.HKD","LU1997245094.SGD","LU0531971595.HKD","SG9999002828.SGD","LU1831875114.USD","LU0823039010.USD","LU1808992512.USD","LU0516422440.USD","LU0516423174.USD","LU2360107325.USD","LU0821914370.USD","LU0651946864.USD","LU2289578879.USD","LU2153591404.USD","LU0072462343.USD","BK1506","LU0650527681.SGD","LU1939255532.USD","BK1575","LU0823426308.USD","BK4141","IE0003851619.USD","LU1328277881.USD","LU0594300419.USD","LU1861214812.USD","BK4588","LU0051755006.USD","002352","LU0509642566.USD","LU0320764755.SGD","LU0561508036.HKD","LU1720050803.USD","EVS.SI","LU2097828557.USD","LU1039395188.USD","BK1521","LU0039217434.USD","03268","01810","LU0312595415.SGD","LU0345776255.USD","LU1282648689.USD","08279","BK0224","LU0048388663.USD","LU2153592121.USD","LU0605514214.HKD","LU2125910849.SGD","LU2152927971.USD","LU2294711473.HKD","BK1149","LU0501845795.SGD","LU2580892862.HKD","LU1721428347.USD","600026","LU1580142542.USD","LU0261950470.USD","BK1193","09995","LU1188198961.HKD","LU1146622755.USD","LU0463099449.HKD","LU0047713382.USD","BK1615","LU0107464264.USD","LU1152091168.USD","LU1303224171.USD","LU0516422952.EUR","LU0594300179.USD","06936","LU2242644610.SGD","LU0449509016.USD","LU1242518931.SGD","LU1719994722.HKD","000333","LU0979878070.USD","LU1956131251.USD","LU0210526637.USD","IE0034224299.USD","LU0117841782.USD","SG9999001093.SGD","603906","LU0611395673.USD","LU1102505929.USD","LU1820825898.SGD","02038","LU0132412106.USD","600115","LU2476274308.USD","LU0823414478.USD","LU2097828474.EUR","LU2449936058.SGD","LU1655091616.SGD","IE0003795394.USD","LU0228659784.USD","LU0348735423.USD","LU0067412154.USD","LU1481107354.HKD","601898","LU0797268264.HKD","IE00B543WZ88.USD","LU0149534421.HKD","01898","300433","LU2477742899.HKD","HXXD.SI","SBHMY","LU2097828805.USD","LU1323998911.USD","LU1242518857.USD","LU0165289439.USD","LU1861219969.SGD","02556","LU2357125470.USD","IE00BD6J9T35.USD","LU0918141887.USD","LU0456827905.SGD","LU0502904849.HKD","IE00B3M56506.USD","LU1807302812.USD","LU0588546209.SGD","LU0048580855.USD","SG9999014674.SGD","LU1969619763.USD","03908","LU0128522157.USD","HK0000286598.CNH","LU1981816686.USD","601995","LU0054450605.USD","SGXZ49509284.SGD","LU0441854154.USD","LU1868837565.USD","LU2249611893.SGD","SG9999000459.SGD","LU0029875118.USD","LU1251922891.USD","SGXZ81163826.USD","BK1523","LU2506951792.HKD","00753","BK1610","LU2348773727.SGD","LU0417516902.SGD","SG9999000327.SGD","02186","LU0823397285.USD","LU2298322129.HKD","LU0607220059.USD","LU0192582467.USD","LU0269904917.USD","LU0143863198.USD","LU1064130708.USD","LU0456846285.SGD","MIUmain","LU0540923850.HKD","LU0724618433.USD","SG9999001846.SGD","LU1781817850.SGD","LU2348774022.SGD","LU0084288322.USD","LU0164865239.USD","LU0828237510.HKD","LU2506952337.HKD","688331","LU2476274720.SGD","LU1770034418.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130423128","title":"LUYE PHARMA's Innovative Drug LY03017 Enrolls First Patient in Chinese Phase II Trial for Alzheimer's Disease Psychosis","url":"https://stock-news.laohu8.com/highlight/detail?id=1130423128","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130423128?lang=en_us&edition=fundamental","pubTime":"2026-04-15 21:08","pubTimestamp":1776258507,"startTime":"0","endTime":"0","summary":"LUYE PHARMA has announced that the first patient has been enrolled in a Phase II clinical trial in China for its self-developed innovative drug, LY03017, which is intended for the treatment of...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1191","BK1161","02186","159992","06978","BK1583","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182767326","title":"Luye Pharma initiates China Phase II trial of LY03017 targeting Alzheimer’s disease-related psychosis","url":"https://stock-news.laohu8.com/highlight/detail?id=1182767326","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182767326?lang=en_us&edition=fundamental","pubTime":"2026-04-15 21:03","pubTimestamp":1776258208,"startTime":"0","endTime":"0","summary":"Hong Kong–listed Luye Pharma Group Ltd. enrolled the first subject in a randomized, double-blind, placebo-controlled Phase II trial of its in-house candidate LY03017 for Alzheimer’s disease-related...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627742632","title":"A Look At Luye Pharma Group (SEHK:2186) Valuation As LY03020 Enters Phase II For Schizophrenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2627742632","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627742632?lang=en_us&edition=fundamental","pubTime":"2026-04-15 00:07","pubTimestamp":1776182827,"startTime":"0","endTime":"0","summary":"Luye Pharma Group (SEHK:2186) has drawn fresh attention after reporting the first patient enrollment in a Phase II trial in China for LY03020, a dual TAAR1 and 5-HT2CR agonist targeting schizophrenia.\nSee our latest analysis for Luye Pharma Group.\nThe LY03020 trial update comes as Luye Pharma Group’s share price sits at HK$2.89, with a 30-day share price return of 18.93% contrasting with a 90-day share price decline of 3.99%. The 1-year total shareholder return of 55.38% stands against a...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2186/luye-pharma-group-shares/news/a-look-at-luye-pharma-group-sehk2186-valuation-as-ly03020-en","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2186/luye-pharma-group-shares/news/a-look-at-luye-pharma-group-sehk2186-valuation-as-ly03020-en","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","02186","BK1191","BK1606","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133445978","title":"LUYE PHARMA Shares Climb Nearly 3% in Morning Session as Self-Developed Drug LY03020 Enrolls First Patient in Chinese Phase II Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1133445978","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133445978?lang=en_us&edition=fundamental","pubTime":"2026-04-14 12:02","pubTimestamp":1776139339,"startTime":"0","endTime":"0","summary":"LUYE PHARMA (02186) rose nearly 3% in morning trading. At the time of writing, the stock was up 2.52%, trading at HK$2.85, with a turnover of HK$53.236 million. The increase follows a recent...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","159992","BK1574","BK1583","BK1161","06978","VXUS","BK4588","02186","BK1191","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137297772","title":"UBS Increases Stake in LUYE PHARMA by 13.95 Million Shares at HK$2.85 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=1137297772","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137297772?lang=en_us&edition=fundamental","pubTime":"2026-04-13 19:26","pubTimestamp":1776079572,"startTime":"0","endTime":"0","summary":"On April 2, UBS purchased an additional 13.9545 million shares of LUYE PHARMA (02186) at HK$2.8547 per share, involving a total consideration of approximately HK$39.84 million. Following this...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","EWH","02186","BK1583","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104880672","title":"LUYE PHARMA's Innovative Drug LY03020 Enrolls First Patient in Chinese Phase II Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1104880672","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104880672?lang=en_us&edition=fundamental","pubTime":"2026-04-08 22:46","pubTimestamp":1775659592,"startTime":"0","endTime":"0","summary":"LUYE PHARMA has announced that the first patient has been enrolled in the China Phase II clinical trial for its self-developed innovative drug, LY03020. LY03020 is the world's first dual-target...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186","BK1574","BK1606","03020","159992","BK1161","06978","BK1583","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625940854","title":"Luye Pharma enrolls first patient in China Phase II trial of LY03020 schizophrenia drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2625940854","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625940854?lang=en_us&edition=fundamental","pubTime":"2026-04-08 22:30","pubTimestamp":1775658646,"startTime":"0","endTime":"0","summary":"Luye Pharma enrolled first patient in China Phase II trial of LY03020, an in-house antipsychotic candidate for acute schizophrenia.No clinical results were presented; trial is designed to generate efficacy, safety, and pharmacokinetic readouts to guide dose selection.Development plan positions LY03020 as a next-generation option aimed at improving symptom control while reducing side-effect burden versus older antipsychotics.Program also cleared to start US clinical testing, supporting parallel China-US development in Luye Pharma’s central nervous system pipeline.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Luye Pharma Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service o","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL6HQMQy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","02186","BK1191","BK1606"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.luye.cn","stockEarnings":[{"period":"1week","weight":-0.0776},{"period":"1month","weight":-0.1986},{"period":"3month","weight":-0.163},{"period":"6month","weight":-0.2365},{"period":"1year","weight":0.1133},{"period":"ytd","weight":-0.1752}],"compareEarnings":[{"period":"1week","weight":-0.0279},{"period":"1month","weight":-0.0269},{"period":"3month","weight":-0.0395},{"period":"6month","weight":0.0171},{"period":"1year","weight":0.0832},{"period":"ytd","weight":0.0008}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Luye Pharma Group Ltd is a company mainly engaged in developing, producing, marketing and selling pharmaceutical products. The Company operates four segments, including Oncology Drugs segment, Cardiovascular System Drugs segment, Alimentary Tract and Metabolism Drugs segment, and Central Nervous System Drugs segment. The Oncology Drugs segment provides Lipusu, Boyounuo, Baituowei, CMNa and Mimeixin and other drugs. The Cardiovascular System Drugs segment provides Xuezhikang, Oukai and Maitongna and other drugs. The Alimentary Tract and Metabolism Drugs segment provides Bei Xi and other drugs. The Central Nervous System Drugs segment provides Seroquel, Ruoxinlin, Rykindo, Meibirui and Jinyouping and other drugs.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.024212},{"month":2,"riseRate":0.333333,"avgChangeRate":0.016158},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.022436},{"month":4,"riseRate":0.5,"avgChangeRate":-0.006455},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.017935},{"month":6,"riseRate":0.363636,"avgChangeRate":0.035296},{"month":7,"riseRate":0.636364,"avgChangeRate":0.018026},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.044846},{"month":9,"riseRate":0.583333,"avgChangeRate":0.045957},{"month":10,"riseRate":0.5,"avgChangeRate":-0.00637},{"month":11,"riseRate":0.5,"avgChangeRate":0.024651},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.012685}],"exchange":"SEHK","name":"LUYE PHARMA","nameEN":"LUYE PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"LUYE PHARMA(02186),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest LUYE PHARMA(02186) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"LUYE PHARMA,02186,LUYE PHARMA股票,LUYE PHARMA股票老虎,LUYE PHARMA股票老虎国际,LUYE PHARMA行情,LUYE PHARMA股票行情,LUYE PHARMA股价,LUYE PHARMA股市,LUYE PHARMA股票价格,LUYE PHARMA股票交易,LUYE PHARMA股票购买,LUYE PHARMA股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"LUYE PHARMA(02186),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest LUYE PHARMA(02186) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}